Breast Cancer: Basic and Clinical Research

Safety and Efficacy of nab-Paclitaxel in the Treatment of Patients with Breast Cancer

Submit a Paper

Breast Cancer: Basic and Clinical Research 2011:5 53-65


Published on 13 Apr 2011

DOI: 10.4137/BCBCR.S5857

Further metadata provided in PDF

Sign up for email alerts to receive notifications of new articles published in Breast Cancer: Basic and Clinical Research


Taxanes are highly active chemotherapeutic agents in the treatment of early-stage and metastatic breast cancer. Novel formulations have been developed to improve efficacy and decrease toxicity associated with these cytotoxic agents. nab-paclitaxel is a solvent free, albumin-bound 130-nanometer particle formulation of paclitaxel (Abraxane®, Abraxis Bioscience), which was developed to avoid toxicities of the Cremophor vehicle used in solvent-based paclitaxel. In a phase III clinical trial, nab-paclitaxel demonstrated higher response rates, better safety and side-effect profile compared to conventional paclitaxel, and improved survival in patients receiving it as second line therapy. Higher doses can be administered over a shorter infusion time without the need for special infusion sets or pre-medications. It is now approved in the US for treatment of breast cancer after failure of combination chemotherapy for metastatic disease or relapse within 6 months of adjuvant therapy, where prior therapy included an anthracycline. Recently, several phase II studies have suggested a role for nab-paclitaxel as a single agent and in combination with other agents for first-line treatment of metastatic breast cancer.




BibTex citation   (BIBDESK, LATEX)


What Your Colleagues Say About Breast Cancer: Basic and Clinical Research
I had a great experience publishing our paper in Breast Cancer: Basic and Clinical Research. The editorial team is very friendly and helpful. I was updated frequently during the entire review and publishing process. The review process is very reasonable and fair. The editor in charge has good judgement on review comments. I would recommend this journal to any researchers who conduct breast cancer research.
Dr Yanfen Hu (University of Texas Health Science Center at San Antonio, San Antonio, TX, USA)
More Testimonials

Quick Links

New article and journal news notification services